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compared with stored component blood therapy for neonates
undergoing cardiopulmonary bypass for cardiac surgery:
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Objective: This study compared the effects of reconstituted fresh whole blood against standard blood component
therapy in neonates undergoing cardiac surgery.
Methods: Patients less than 1 month of age were randomized to receive either reconstituted fresh whole blood
(n ¼ 31) or standard blood component therapy (n ¼ 33) to prime the bypass circuit and for transfusion during
the 24 hours after cardiopulmonary bypass. Primary outcome was chest tube drainage; secondary outcomes in-
cluded transfusion needs, inotrope score, ventilation time, and hospital length of stay.
Results: Patients who received reconstituted fresh whole blood had significantly less postoperative chest tube
volume loss per kilogram of body weight (7.7 mL/kg vs 11.8 mL/kg; P¼ .03). Standard blood component therapy
was associated with higher inotropic score (6.6 vs 3.3; P ¼ .002), longer ventilation times (164 hours vs 119
hours; P ¼ .04), as well as longer hospital stays (18 days vs 12 days; P ¼ .006) than patients receiving reconsti-
tuted fresh whole blood. Of the different factors associated with the use of reconstituted fresh whole blood, lower
platelet counts at 10 minutes and at the end of cardiopulmonary bypass, older age of cells used in the prime and
throughout bypass, and exposures to higher number of allogeneic donors were found to be independent predictors
of poor clinical outcomes.
Conclusions: Reconstituted fresh whole blood used for the prime, throughout cardiopulmonary bypass, and for
all transfusion requirements within the first 24 hours postoperatively results in reduced chest tube volume loss and
improved clinical outcomes in neonatal patients undergoing cardiac surgery.Earn CME credits at
http://cme.ctsnetjournals.org
Morbidity andmortality during neonatal heart surgery for re-
pair of congenital heart disease has dramatically improved
over the past decade; however, it remains higher than in
older children and adults.1 This is partly associated with
the exaggerated disruptions of coagulation and the stimula-
tion of the inflammatory response in neonates undergoing
cardiopulmonary bypass (CPB) for congenital heart dis-
ease.1-3 The disturbances in coagulation that lead to postop-
erative bleeding in neonates are the result of interactions
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hemostatic system immaturity, hemodilution, systemic
inflammation, prolonged bypass times, and the use of deep
hypothermic circulatory arrest (DHCA).4-7
Increased bleeding and allogeneic blood transfusion re-
quirements have been shown to vary inversely with the age
and size of infants requiring cardiac surgery.8 Transfusion
of allogeneic blood products is associated with a number of
adverse effects such as infectious agent transmission, the de-
velopment of postoperative infections, and other transfusion
reactions.9-12 Previous studies of the use of fresh whole blood
to either prime the CPB circuit or meet postoperative transfu-
sion requirements have reported conflicting results.13,14 No
studies have compared the use of reconstituted fresh whole
blood (RFWB) versus standard blood component therapy
to prime the CPB circuit and replace postoperative blood
loss within the first 24 hours after surgery. We sought to de-
termine whether the use of RFWB during CPB and for the
first 24 hours postoperatively would improve clinical out-
comes compared with standard blood component therapy.
METHODS
Study Design
This prospective randomized controlled clinical trial was conducted
from August 2001 until March 2005. Delays and scheduling conflictsurgery c December 2008




ACT ¼ activated clotting time
CBS ¼ Canadian Blood Services
CCCU ¼ cardiac critical care unit
CPB ¼ cardiopulmonary bypass
DHCA ¼ deep hypothermic circulatory arrest
IL-8 ¼ interleukin 8
PRBC ¼ packed red blood cell
RFWB ¼ reconstituted fresh whole blood
TNF ¼ tumor necrosis factor
initially created by the severe acute respiratory syndrome (SARS) epidemic
(March 2002) as well as difficulties in coordinating operations, patient con-
sent, and blood acquisition explain why a lengthier enrollment period was
necessary. The surgeons were blinded to the patients’ group randomization,
whereas perfusion, anesthesia, and cardiac critical care unit (CCCU) staff
were unblinded. Institutional research ethics board approval was granted
at The Hospital for Sick Children, Toronto, Ontario, Canada, with written
informed consent obtained from the legal guardian of each patient before en-
rollment into the study randomization. An independent safety committee
oversaw the study with no member having any clinical responsibilities for
any of the study subjects and no ties to any of the study investigators.
Sixty-four patients met the inclusion criteria of being less than 1 month of
age and scheduled for elective cardiac surgery requiring CPB. Exclusion cri-
teria included emergency surgery and patients known to have a pre-existing
coagulopathy. Subjects were randomized in blocks of 4 to 6 patients to re-
ceive either RFWB in the prime of the CPB circuit and for all transfusion
requirements up to 24 hours postoperatively in the treatment group
(n ¼ 31) or standard blood component therapy in the control group
(n¼ 33). Required sample size was calculated on the basis of previous study
of fresh whole blood versus component therapy.13 It was calculated that
a sample size of 50 patients would detect a 50% reduction in chest tube
volume loss with alpha of.05 and power of 90%.
Blood Product Preparation
All blood products used for both study groups were collected from ran-
dom volunteer donors and processed according to Canadian Blood Services
(CBS) standard operating procedure. Routine testing for infectious agents
was performed on all donated blood before issue from CBS. In both study
groups, CBS required that all donor blood be separated into components
(red blood cells, random donor platelets, and fresh frozen plasma) immedi-
ately after collection and leukocyte reduced by filtration before storage. All
donor blood was collected in bags containing the anticoagulant solution
citrate phosphate double dextrose. AS-3 (Nutricel; Haemonetics, Braintree,
Mass) preservative was added to packed red blood cell (PRBC) components
and stored at 1C to 6C. AS-3 was subsequently removed from all PRBC
before release from the Blood Transfusion Laboratory of The Hospital for
Sick Children as per standard hospital protocol for neonatal patients. All
plasma was frozen within 8 hours of donation and stored at18C or less.
Platelets were continually agitated during storage at 20C to 24C after
separation from platelet-rich plasma by hard spin centrifugation.
When patients were randomized to the treatment arm, CBS was notified
and designated 2 units of ABO-compatible single random donor blood from
two separate donors to be released to the hospital’s blood transfusion labo-
ratory. On the morning of the operation, one of the RFWB units was pre-
pared by reconstituting the components from the single donor that had
been processed as previously described. The second unit of RFWB was
prepared and released as required. All RFWB units were collected 2 days
before the morning of the operation. Patients in the control group receivedThe Journal of Thoracic and CaABO-compatible stored blood components as per standard hospital proto-
col. PRBC and platelets were irradiated on the morning of the operation,
before either reconstitution or release as individual components, depending
on the randomization. Platelet components used in the control group were
random single donor platelets collected 2 to 5 days (median 4 days) before
surgery that were either in their original state or further concentrated at the
discretion of the attending anesthesiologist.
Anesthesia Management (Intraoperative)
Anesthesia was induced with sodium thiopentone (up to 5 mg/kg) and
fentanyl (20 mg/kg) and muscle relaxation with pancuronium (0.1 mg/kg).
An appropriate-sized endotracheal tube was placed and anesthesia was
maintained with isoflurane in air and oxygen with supplemental doses of
fentanyl as clinically indicated. All patients were given aprotinin (Trasylol;
Bayer AG, Leverkusen, Germany) before CPB at a dose of 50,000 KIU/kg
after a test dose of 1,000 KIU/kg. Cefazolin (Ancef; GlaxoSmithKline,
London, United Kingdom), 40 mg/kg, was given for wound prophylaxis.
Patients undergoing DHCA were given methylprednisolone 30 mg/kg. An-
ticoagulation was initiated with a dose of 300 IU of heparin sulfate per kilo-
gram body weight with a target activated clotting time (ACT) of more than
480 seconds before the institution of CPB. Additional heparin was given
during CPB when the ACT was less than 450 seconds. Protamine sulfate
was given in a 1:1 ratio to reverse anticoagulation based on the initial hep-
arin dose, and additional doses were given based on the subsequent ACT.
Perfusion Management (CPB)
The CPB circuit priming solution was composed as follows: electrolyte
solution (Plasma-Lyte 148; Baxter Healthcare, Deerfield, Ill), mannitol 0.25
g/kg, sterile water 50 mL, and 25% albumin 75 mL. The randomized blood
product, either RFWB or PRBC component, was added to achieve a CPB
hematocrit value of 22% to 24%. Cefazolin, 40 mg/250 mL of prime vol-
ume, 10% calcium chloride, and heparin sulfate, 2 IU/mL of prime, were
also added. The total volume was approximately 400 mL. Aprotinin was
added to the prime at a dose of 100,000 KIU/100 mL of prime volume after
the test dose was safely given. Ultrafiltration was used during CPB to
remove any excess fluid added throughout the surgical procedure.
Blood flow was maintained on CPB at 120 to 150 mL/kg body weight.
Patients undergoing DHCA were actively cooled to a rectal temperature of
15C and pH-stat blood gas management was used during cooling. All other
patients were allowed to passively cool to 34C body temperature and
alpha-stat blood gas management was used throughout.
Myocardial protectionwas achievedwith blood cardioplegia using a blood
and crystalloid mixture at a 2:1 ratio. Additional mannitol was given before
aortic crossclamp removal at a dose of 0.5 mg/kg. Patients received blood
products, either RFWB or PRBC, to maintain a hematocrit value between
22% and 24% during CPB and to reach a target hematocrit value of 28%
in acyanotic patients and 32% in cyanotic patients before weaning from
CPB. Patients randomized to receive component blood therapy received 1
unit of fresh frozen plasma with heparin sulfate (2 IU/mL) added before aortic
crossclamp removal.All patients underwentmodifiedultrafiltration afterCPB.
After CPB, control patients were given components for volume replace-
ment according to the following transfusion guidelines: PRBC when the
hematocrit valuewas less than 28% (acyanotic patients) or 32% (cyanotic pa-
tients), platelets (1U/6 kg)when theplatelet countwas less than100,000/mm3,
cryoprecipitate if the fibrinogen level was less than 1.0 g/L, and additional
fresh frozenplasma for ongoingbleeding. Patients randomized to the treatment
group receivedRFWBfor hemostasis and volume replacement as required un-
til both available units were used, after which standard blood component ther-
apy was used according to the aforementioned transfusion guidelines.
Data Collection
Arterial blood samples were obtained from all patients after the place-
ment of the arterial line, 10 minutes after to the start of CPB, before aorticrdiovascular Surgery c Volume 136, Number 6 1443
Congenital Heart Disease Gruenwald et al
C
H
Dcrossclamp removal, at the end of CPB, after protamine and at 4 and 24
hours in the CCCU. Additional blood samples were taken every 4 hours
in the CCCU and results were used to guide transfusion protocols as previ-
ously described. Blood samples were analyzed for complete blood count,
fibrinogen, and biochemistry. Interleukin 8 (IL-8) and tumor necrosis factor
(TNF-a) levels were measured at induction of anesthesia and 4 and 24
hours after arrival in the CCCU. IL-8 and TNF-a levels were measured
by immunometric assay (Immulite analyzer; Euro/DPC, Llanberis, United
Kingdom). The surgeon gave a subjective assessment of intraoperative
bleeding graded as mild, moderate, or severe before leaving the operating
room. Chest tube drainage and hematocrit value within the first 24 hours
after the CCCU admission were measured.
Blood transfusion during CPB and for 24 hours postoperatively was
tabulated by the total volume and the type and number of blood product
units transfused. The transfusion guidelines used in the CCCU were the
same as those used immediately after CPB. An inotropic support score
was calculated at 24 hours after arrival in CCCU by means of the following
formula, using drug dosages expressed as micrograms per kilogram per
minute: dopamine þ dobutamine þ (epinephrine 3 100) þ (milrinone 3
10).14 Total ventilation hours and CCCU and hospital length of stay were
also compared.
Statistical Analysis
Data are described as frequencies, medians with ranges, and means with
standard deviations as appropriate. Baseline characteristics and outcomes
were compared with Fisher’s exact tests, c2 tests, Kruskal–Wallis analysis
of variance, and the Student t tests as appropriate. To account for repeated
measures and multiple comparisons, differences between groups for serial
measures of laboratory and inflammatory marker variables were tested in
multivariable mixed linear regression modeling using a compound symme-
try covariance structure. The compound symmetry covariance structure
calculates and accounts for the correlation between multiple observations
on the same patients. Multivariable regression models were created using
maximum likelihood estimates to determine the independent effect of age
of blood cells in the prime, allogeneic donor exposures, and platelet count
on medical outcome of interest while accounting for correlation between
these variables. Given a skewed distribution for the inflammatory marker
variables, the distribution was normalized with a logarithmic transforma-
tion. All analyses were performed with SAS statistical software version
9.1 (SAS Institute, Inc, Cary, NC).
RESULTS
Clinical Outcomes
Experimental groups were similar in terms of demo-
graphic and intraoperative characteristics (Tables 1 and 2).
Norwood surgery and requirements for steroid were not
found to affect the relationship between blood transfusions
and surgical outcomes, even though they were unevenly dis-
tributed between groups. All patients survived to CCCU dis-
charge. One patient in the RFWB group died before hospital
discharge on day 331 after surgery.
As a result of the study design, the component group had
significantly higher mean blood donor unit exposures (7 4
units) than the RFWB group (3  2 units) when both CPB
and postoperative blood transfusion requirements were in-
cluded (P< .0001).
Blood cells used in the prime were significantly older in
the component group (14 8 days) than in the RFWB group
(2 days) (P< .0001). There was no significant difference
between the two groups in the median total volume trans-1444 The Journal of Thoracic and Cardiovascular Sufused within the study period (93 [24–319] mL/kg in the
RFWB group vs 69 [26–271] mL/kg in the control group;
P ¼ .55). Fourteen patients in the RFWB group received
additional blood component therapy after the 2 allotted units
of RFWB were used.
The component group had significantly higher median
chest tube loss (11.8 [4.0–44.1] mL/kg) than the RFWB
group (7.7 [2.0–34.6] mL/kg) over the first 24 hours after
CCCU admission (P ¼ .03) (Table 3). There was no signifi-
cant difference in the measured hematocrit value of chest
tube drainage between the two groups. The bleeding was
described by the surgeon more frequently as moderate or
severe in the component group (27/31, 82%) than in the
RFWBgroup (17/33, 55%;P¼ .03). There was a statistically
significant correlation between surgeon’s assessment of
bleeding and postoperative chest tube volume loss (P< .05).
The RFWB group had a significantly lower median
inotropic score (3.3; 0–9.9) at 24 hours in the CCCU than
did the component group (6.6; 0–14.9; P ¼ .002).




(n ¼ 33) P value
Gender, No. (%)
Male 19 (61) 17 (52) 0.44
Female 12 (39) 16 (48)
Age (d) 15  10 14  11 0.65
Surgeon, No. (%)
1 23 (74) 24 (73) 0.90
2 3 (10) 3 (9)
3 5 (16) 6 (18)
Operation type, No. (%) 0.60
Norwood 6 (19) 10 (30)
Arterial switch 19 (61) 17 (52)
Truncus repair 2 (6) 2 (6)
Tetralogy repair 0 (0) 1 (3)
TAPVD repair 1 (3) 0 (0)
VSD, Coarct 3 (10) 3 (9)
Weight (kg) 3.5  0.6 3.4  0.4 0.80
RFWB, Reconstituted fresh whole blood; TAPVD, total anomalous pulmonary venous
drainage; VSD, ventricular sseptal defect; Coarct, coarctation.








Mean CPB time (min  SD) 136  58 126  41 .42
Mean aortic crossclamp time (min  SD) 79  26 73  30 .43
Patients with DHCA 12 (39%) 15 (45%) .59
Arterial switch operation with DHCA 2 2
Median circulatory arrest time (min) 8 (3–27) 11 (1–38) .68
Norwood operation with SCP 5 9
Mean OR time (min  SD) 397  84 398  89 .98
RFWB, Reconstituted fresh whole blood; CPB, cardiopulmonary bypass; SD, standard
deviation; OR, operating room; DHCA, deep hypothermic circulatory arrest; SCP,
selective cerebral perfusion.rgery c December 2008
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tion was significantly reduced in the RFWB group when
compared with the component group (119 [28–480] hours
vs 164 [54–192] hours; P ¼ .04).
There was no significant difference in the incidence of
postoperative infections (6/33 [18%] in the component
group vs 3/31 [10%] in the RFWB group [P ¼ .48]). Infec-
tions were either surgical site or blood-borne infections and
included a positive culture.
The component group patients had a somewhat longer
median CCCU length of stay (7 (1–39] days) than the
patients in the RFWB group (5 [3–20] days; P¼ .17), albeit
not significant. The median hospital length of stay in days
for the survivors was significantly longer for the component
group patients than for the RFWB group patients (18 [7–79]
days vs 12 [6–36] days; P ¼ .006) (Table 3).
The proportion of patients undergoing the Norwood oper-
ation was somewhat unequal between groups. A subanalysis
including patients undergoing the Norwood operation only
was performed (Table 4), and it was found that the relation-
ship between RFWB and improved postoperative outcomes
cannot be attributed to the slightly higher number of Nor-
wood patients in the control group versus the RFWB group.









Chest tube loss 0–4 h
CCCU, mL/kg (range)
7.1 (0.6–30.0) 5.7 (1.8–45.6) .76
Chest tube loss 4–24 h
CCCU, mL/kg (range)
7.7 (2.0–34.6) 11.8 (4.0–44.1) .03
Bleeding assessed as
moderate or severe
17 (55%) 27 (82%) .03
Secondary outcome measures
Inotropic support score
(ISS) at 4 h CCCU
6.6 (0–20.0) 9.5 (0–20.0) .53
Inotropic support score
(ISS) at 24 h CCCU
3.3 (0–9.9) 6.6 (0–14.9) .002
Ventilation in hours,
median (range)
119 (28–480) 164 (54–912) .04
CCCU LOS in days,
median (range)
5 (3–20) 7 (1–39) .17
Hospital LOS in days,
median (range)
12 (6–36) 18 (7–79) .02
Transfusion characteristics
Blood produce exposure,
mean units  SD
3.2  1.9 6.9  3.8 <.0001
Transfusion requirements
postop, mL/kg (range)
33 (0–177) 43 (4–160) .55
Age of donor blood
products, days
1.9  0.3 13.6  7.7 <.0001
RFWB,Reconstituted fresh whole blood;CCCU, cardiac critical care unit; LOS, length
of stay; SD, standard deviation.The Journal of Thoracic and CaRegression models corrected for the use of corticosteroids,
deep hypothermia, or staff surgeon did not alter the differ-
ence between improved clinical outcomes and the use of
RFWB.
Laboratory Measurements
At induction, all patients had similar values for arterial
blood gases, fibrinogen, electrolytes, magnesium, calcium,
glucose, lactate, and hematologic indices (Figure 1). Lactate,
potassium, and calcium levels were significantly higher in
the CPB circuit prime in the component group (P< .001).
Although statistical differences were observed at sporadic
time points in sodium, calcium, magnesium, glucose, and
bicarbonate, no clinically relevant differences were ob-
served between groups. There were no significant differ-
ences between groups at any time in colloid osmotic
pressure, base deficit, pH, and white cell count.
ACT was significantly higher in the component group at
the time of aortic crossclamp removal (P ¼ .001). Fibrino-
gen levels were significantly higher in the component group
after protamine (P ¼ .002) but remained similar across
groups thereafter. Serum potassium level was significantly
higher in the component group in the CPB circuit prime
(P< .0001) after 10 minutes of CPB (P ¼ .001), at the
time of aortic crossclamp removal (P ¼ .008), and at the
end of CPB (P ¼ .004). Hematocrit level was significantly
higher in the component group after 10 minutes of CPB
(P ¼ .0001) and at the end of CPB (P< .0001) and in the
postprotamine period (P ¼ .006), with similar findings for
hemoglobin (data not shown). Platelet count was signifi-
cantly lower in the component group after 10 minutes of
CPB (P ¼ .02) and at the end of CPB (P ¼ .006).
Induction values for the markers of systemic inflamma-
tion, IL-8, and TNF-a, were similar between groups
(P ¼ .59 for IL-8; P ¼ .18 for TNF-a). There was a signifi-
cant increase in both markers measured at 4 hours after CPB
and 24 hours after CBP, with a significantly greater increase
seen in the component group compared with the RFWB
group (þ84 vs RFWB at 4 hours [95% confidence interval:
38–112], P ¼ .003 for IL-8; þ10 vs RFWB at 4 hours
[95% confidence interval: 2–15], P ¼ .02 for TNF-a).
Age of Cells in Prime, Allogeneic Donor Exposures,
and Platelet Count at the End of Bypass
The use of RFWB as described in the Methods section
affects 3 important parameters of blood transfusion: the
age of infused cells, the number of allogeneic donor expo-
sures, and the platelet count during bypass. Because the
effect of RFWB is likely multifactorial in nature, further
analyses were performed to quantify the relative effect of
each component. In univariate analysis, chest tube loss at
24 hours in CCCU, inotropic score at 24 hours, duration
of ventilation, and hospital stay were all found to be signif-
icantly associated with age of blood product given in therdiovascular Surgery c Volume 136, Number 6 1445
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RFWB (n ¼ 6) Control (n ¼ 10) P value
Primary outcome measures
Gender (male) 1/6 5/10 .20
Age (d) 10 (3–30) 9 (5–33) .79
Weight (kg) 3.5  0.5 3.4  0.4 .28
Mean CBP time, min  SD 128  28 122  23 .92
Mean aortic crossclamp time, min  SD 71  16 61  11 .14
Median circulatory arrest time, min 8 (3–13) 2 (0–25) .07
Mean OR time, min  SD 372  69 402  39 .08
Chest tube loss 0–4 h CCCU, mL/kg (range) 9.0 (7.7–29.4) 9.8 (4.3–53.4) .75
Chest tube loss 4–24 h CCCU, mL/kg (range) 10.3 (4.3–33.1) 13.4 (4.1–51.7) .45
Bleeding assessed as moderate or severe 2/6 9/10 .04
Inotropic support score (ISS) at 4 h CCCU 9.1 (0.0–19.9) 6.6 (5.0–16.9) .73
Inotropic support score (ISS) at 24 h CCCU 5.0 (0.0–6.6) 8.5 (0.0–11.6) .06
Ventilation in hours, median (range) 264 (163–361) 170 (121–380) .39
CCCU LOS in days, median (range) 12 (7–19) 9 (6–16) .36
Hospital LOS in days, median (range) 22 (17–36) 21 (16–25) .42
Blood product exposure, mean units  SD 3.8  1.5 7.0  2.7 .01
Transfusion requirements postop, mL/kg (range) 103 (0–177) 37 (16–102) .13
Age of donor blood products in days 1.5  0.5 15.1  9.3 .001
RFWB, Reconstituted fresh whole blood; CPB, cardiopulmonary bypass; SD, standard deviation; OR, operating room; CCCU, cardiac critical care unit; LOS, length of stay.prime and throughout CPB, exposure to allogeneic donors,
and platelet count at the end of bypass. In multivariable anal-
ysis (Table 5), lower platelet count at the end of bypass,
older age of blood product given in the prime and throughout
CPB, and exposure to higher number of allogeneic donors
were found to be independent predictors of higher chest
tube loss at 24 hours and longer duration of ventilation.
Only lower platelet count at the end of bypass and exposure
to higher number of allogeneic donors were independent
predictors of higher inotropic score at 24 hours. Lower plate-
let count at the end of bypass and older age of blood cells
given in the prime and throughout bypass were found to
be independent predictors of longer duration of hospital
stay. Of interest, the relationship observed between platelet
counts at the end of CPB and clinical outcomes is replicated
by platelet counts at 10 minutes during CPB.
Discussion
Neonates undergoing CPB for open cardiac surgery are
generally obligated to receive blood transfusions owing to
perioperative bleeding exacerbated by pre-existing coagula-
tion defects and by the use of CPB.6,8 There are risks to
blood transfusion and morbidity associated with postopera-
tive bleeding.9-11 Efforts should be made to reduce alloge-
neic donor exposure. The use of fresh whole blood has
been shown to reduce postoperative bleeding in infant
patients. However, recent transfusion medicine standards
do not support its widespread usage.13,15 The preparation
of the RFWB product used for our study followed the current
CBS and hospital transfusion laboratory standard operating
procedures, including duration of blood storage. The recon-
stituted product used in this study may be superior to tradi-1446 The Journal of Thoracic and Cardiovascular Stional fresh whole blood owing to pre-storage leukocyte
depletion and the storage of platelets at room tempera-
ture.16,17 Pre-storage leukocyte depletion is a standard for
blood component preparation in Canada, with the current
filters reducing the number of leukocytes present in blood
by 4 logs (104), a value below which it is believed that
alloimmunization or suppression does not occur.18 Platelets
stored at room temperature exhibit better hemostatic proper-
ties than when stored at cold temperatures, which is routine
in traditional whole blood storage.19
The neonates who received RFWB had significantly
improved clinical outcomes, including less postoperative
chest tube volume loss during the first 24 hours in the
CCCU, significantly lower inotropic scores, decreased
ventilation time, and reduced hospital length of stay.
It was demonstrated by this study that three factors
affected by the use of RFWB are independently contributing
to these improved outcomes: a higher platelet count at 10
minutes and at the end of CPB, a reduced number of alloge-
neic donor exposures, and younger age of blood products.
Patients in the RFWB group were exposed to a signifi-
cantly reduced number of donors, which was in part a result
of the study design coupled with a reduction in postoperative
chest tube volume loss. The significantly reduced inotropic
score, ventilation time, and hospitalization in the RFWB
patient group was shown to be independently associated
with a lower number of donors exposures.
A higher platelet count at 10minutes and at the end of CPB
was associated with significantly reduced chest tube volume
loss and is supported by other investigators.6 Therefore, the
results indicate that it is important to use RFWB for priming
the CPB circuit, as well as throughout CPB.urgery c December 2008
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trol groupwas 14 days and themedian age of the plateletswas
4 days (current standard for CBS). An increase in the length
of storage of PRBC has been associated with an increase in
the risk of postoperative pneumonia and an increased dura-
tion of stay in the cardiac surgical population.20-22 Further-
more, the transfusion of platelets stored for less than 48
hours has been shown to be associated with larger increases
in posttransfusion platelet increments and longer platelet
transfusion intervals.23 The difference in the age of the blood
used between the two study groups contributed to the
improved clinical outcomes in the RFWB group.
Interestingly, this study observed that the markers of
inflammation measured, IL-8 and TNF-a, experienced a sig-
nificantly greater increase in the component group as com-
pared with the RFWB group. Previous studies have shown
FIGURE 1. Serial laboratorymeasurements. Only laboratory variables that showed a significant interaction between intervention assignment and time period
are shown. Data presented are least square means with the error bar representing the standard error of the mean, derived from mixed linear regression analysis
adjusted for repeatedmeasures, with only significantP values reported from themultivariable analysis. *P<.05.ACT,Activated clotting time;CCCU, cardiac
critical care unit; CPB, cardiopulmonary bypass.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 6 1447
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outcomes
Univariate MLE analysis Multivariable
P valuePE SE P value
Higher chest tube loss at 24 hours
Lower platelet count at the end of bypass (3109/L) 0.0026 (0.0004) <.0001 <.0001
Older age of blood product in prime (d) 0.0120 (0.0010) <.0001 <.0001
Higher number of allogeneic donors exposure 0.0241 (0.0024) <.0001 .06
Higher inotropic score at 24 hours
Lower platelet count at the end of bypass (3109/L) 0.0029 (0.0012) .02 .004
Older age of blood product in prime (d) 0.0087 (0.0029) .003 .10
Higher number of allogeneic donors exposure 0.0310 (0.0064) <.0001 .005
Longer duration of ventilation (h)
Lower platelet count at the end of bypass (3109/L) 0.0041 (0.0002) <.0001 <.0001
Older age of blood product in prime (d) 0.0129 (0.0005) <.0001 <.0001
Higher number of allogeneic donors exposure 0.0206 (0.0012) <.0001 <.0001
Longer duration of hospital stay (d)
Lower platelet count at the end of bypass (3109/L) 0.0042 (0.0007) <.0001 <.0001
Older age of blood product in prime (d) 0.0102 (0.0016) <.0001 <.0001
Higher number of allogeneic donors exposure 0.0161 (0.0039) <.0001 .67
Parameters are reported for the univariate associations while P values are reported for both univariate and multivariable associations. MLE, Maximum likelihood estimate;
PE, parameter estimate; SE, standard error.that an IL-8 level measured after CPB in children is a marker
of early postoperative morbidity.24
Results from this study are in contradiction with a previ-
ous randomized controlled trial of fresh whole blood versus
component therapy.14 Mou and colleagues14 found no dif-
ferences in postoperative outcomes between experimental
groups, and some secondary clinical measures showed an
advantage for the component therapy. A few major issues
with the study design are to be considered when contrasting
both studies. First, the use of fresh whole blood for priming
the bypass circuit only while using component therapy for
further transfusion requirements might have obscured the ef-
fect of fresh whole blood. Second, the use of blood (in both
arms of the study) that had not been leukodepleted could off-
set gains made by using fresh whole blood. Finally, morbid-
ity andmortality rates in the postoperative period might have
confounded the results and overshadowed any improve-
ments made with the use of fresh whole blood. Furthermore,
another study byManno and colleagues13 also found that the
use of fresh whole blood for priming and for perioperative
and postoperative requirements was associated with
improved clinical outcomes, thus supporting the results of
the current study.
While this study put forward the clinical advantages of
using fresh whole blood in the context of neonatal cardiac
surgery, logistical issues may prevent replicating this strat-
egy in a routine context. Nonetheless, many features of
a fresh reconstituted whole blood strategy show that they
are independently associated with improved outcomes:
fresher blood, smaller number of exposures, and higher
platelet count during bypass. Many of these features can
be obtained with this modified component therapy protocol1448 The Journal of Thoracic and Cardiovascular Seven when single donor whole blood is unavailable. As
such, when single donor RFWB is not practical, an alterna-
tive strategy may include the use of reconstituted fresh com-
ponents from multiple donors. This may replicate the effect
of RFWB without the challenge of obtaining single donor
products. The addition of fresh platelets in the prime will
achieve a higher platelet count on initiation of bypass and
throughout surgery, which was found to be an important
element of the effect of RFWB. Because this assumption
is not yet supported by research, future studies could focus
on methodologies to emulate the effect of RFWB using
different techniques when RFWB is not available.
This study must be viewed in light of some limitations.
The enrollment period had to be extended owing to logistic
issues that meant only a limited proportion of eligible neo-
nates could be enrolled in the study. However, the date of
surgery was not found to be associated with clinical out-
comes. Further, the age of red cells and platelets in the com-
ponent therapy group was older than that used in other
centers but was within acceptable CBS standard operating
procedures. The assessment of blood loss in the postopera-
tive period only took into account drainage from chest tubes
and did not account for potential blood collecting in the pleu-
ral cavity or blood accumulating in the mediastinum for pa-
tients with open chests in the intensive care unit. Despite the
fact that using chest tube volume loss as a surrogate for post-
operative bleeding could underestimate total blood loss,
there are no reasons to believe that this difference would
be unevenly distributed between experimental groups. Fi-
nally, previous surgical studies have also used chest tube
volume loss as a surrogate for postoperative bleeding in pe-
diatric patients undergoing open cardiac surgery.urgery c December 2008
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DIn conclusion, this study advocates the use of single donor
RFWB to prime the bypass circuit, throughout CPB, and for
transfusion requirements during the first 24 hours after
surgery. This technique was associated with a significant
reduction in chest tube volume loss for neonatal patients
undergoing CPB for cardiac surgery. Furthermore, those pa-
tients who received RFWB had significantly better clinical
outcomes, including decreased need for inotropic support,
reduced ventilation time, and shorter hospital length of
stay. In light of these data, adopting a modified practice of
using platelets in the prime, fresher blood components,
and limiting donor exposure could be highly beneficial.
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